Pleural Effusion Clinical Trials

Rancho Mirage : Desert Hematology Oncology Medical Group, Inc.

First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer

Denver : National Jewish Medical Center

Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter

Kansas City : Kansas City Cancer Center

First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer

Baltimore : Johns Hopkins University

Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter

Boston : Beth Israel Deaconess Medical Center

Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter

Burlington : Lahey Clinic

Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter

Hackensack : Hackensack University Medical Center

First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer

New York : Memorial Sloan-Kettering Cancer Center

Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma

Durham : Duke University Medical Center

Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter

Temple : Scott and White Memorial Hospital & Clinic

Alteplase for Treatment of Empyema and Complicated Parapneumonic Effusion

Salt Lake City : University of Utah

Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter

Sofia : Department of Medical Oncology, Specialized Hospital for Active Treatment of Oncological Diseases

First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer

Varna : Medical Oncology Clinic, Multiprofile Hospital for Active Treatment

First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer

Veliko Tarnovo : Department of Medical Oncology, Complex Oncology Center

First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer

Beijing : PLA 304 hospital

Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer

Nanjing : The 81st Hospital of Chinese PLA

Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites

Qingdao : The Affiliated Hospital of Medical College, QingDao University

Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites

Shanghai : Fudan University Shanghai Cancer Center

Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites

Anand : M S Patel Cancer Centre, Shree Krishna Hospital

First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer

Chennai : Dr. Kamakshi Memorial Hospital

First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer

Coimbatore : G Kuppuswamy Naidu Memorial Hospital, Valvadi Narayanaswamy Cancer Centre

First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer

Hyderabad : NIZAM's Institute of Medical Sciences

First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer

Kolkata : Orchid Nursing Home

First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer

View More »

Nashik : Shatabdi Super Speciality Hospital

First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer

Nashik : Curie Manavata Cancer Centre

First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer

Pune : Noble Hospital

First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer

Mexico City : Instituto Nacional de Cancerologia

First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer

Arkhangelsk : State Medical Institution: Arkhangelsk Regional Clinical Oncology Center

First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer

Chelyabinsk : State Therapeutical and Prophylatic Institution: Chelyabinsk Regional Clinical Oncology Center

First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer

Kursk : State Medical Instituion Kursk Regional Oncology Center

First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer

Moscow : Non-State Medical Institution: Central Clinical Hospital #2

First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer

Saint-Pertersburg : St. Petersburg State Healthcare Institution: City Clinical Oncology Center

First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer

Dnipropetrovsk : Public Institution: Dnipropetrovsk City Multispeciality Clinical Hospital #4

First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer

Donetsk : Public Clinical Treatment and Prophylaxis Instituion: Donetsk Regional Antitumor Center

First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer

Ivano-Frankivsk : Ivano-Frankivsk Regional Oncology Center

First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer

Kharkiv : Public Healthcare Instituion: Kharkiv Regional Clinical Oncology Center

First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer

Kyiv : Kyiv City Clinical Oncology Center

First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer

View More »

Uzhhorod : Zakarpattia Regional Clinical Oncology Center

First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer